(2'-methylbiphenyl-2-yl)methanamine | 153850-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2'-methylbiphenyl-2-yl)methanamine
• 英文别名: 2-aminomethyl-2'-methylbiphenyl；(2'-Methyl[1,1'-biphenyl]-2-yl)methanamine；[2-(2-methylphenyl)phenyl]methanamine
• CAS: 153850-89-6
• 化学式: C₁₄H₁₅N
• 分子量: 197.28
• InChiKey: KMKYKXAYRUYGKI-UHFFFAOYSA-N

物化性质

• 沸点：
  332.9±21.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (2'-methylbiphenyl-2-yl)methanamine 在 碘苯二乙酸 、 碘 、 三乙胺 作用下， 以 硝基甲烷 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-methylphenanthridine
  参考文献：
  名称：

  通过碘支持的分子内CH胺化和在可见光下的氧化反应合成菲啶。

  摘要：

  在这里，我们报告了在温和的条件下从2-biarylmethanamines无金属和经济的步骤合成菲啶。该反应包括碘在空气和良性可见光下的分子内CH–H胺化和5,6-二氢菲啶的氧化。机制研究表明，可见光在这两个步骤中都起着关键作用。

  DOI：

  10.1021/acs.joc.0c01390
• 作为产物：
  描述：

  2-碘氰基苯 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (2'-methylbiphenyl-2-yl)methanamine
  参考文献：
  名称：

  Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression

  摘要：

  5-HT7 receptor (5-HT7R) is a promising target for the treatment of depression and neuropathic pain. 5-HT7R antagonists exhibited antidepressant effects, while the agonists produced strong anti-hyperalgesic effects. In our efforts to discover selective 5-HT7R antagonists or agonists, N-biphenylylmethyl 2-methoxyphenylpiperazinylalkanamides 1 were designed, synthesized, and biologically evaluated against 5-HT7R. Among the synthesized compounds, N-2'-chlorobiphenylylmethyl 2-methoxyphenylpiperazinylpentanamide 1-8 showed the best binding affinity with a Ki value of 8.69nM and it was verified as a novel antagonist according to functional assays. The compound 1-8 was very selective over 5-HT1DR, 5-HT2AR, 5-HT3R, 5-HT5AR and 5-HT6R and moderately selective over 5-HT1AR, 5-HT1BR and 5-HT2CR. The novel 5-HT7R antagonist 1-8 exhibited an antidepressant effect at a dose of 25mg/kg in the forced swimming test in mice and showed a U-shaped dose-response curve which typically appears in 5-HT7R antagonists such as SB-269970 and lurasidone.

  DOI：

  10.1016/j.bmc.2014.07.026

文献信息

• Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20070003539A1

  公开（公告）日：2007-01-04

  The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• [EN] NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS ARYLES SUBSTITUÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES EN TANT QU'AGENTS ANTI-VIH
  申请人：CELLVIR

  公开号：WO2010066847A1

  公开（公告）日：2010-06-17

  The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.

  本发明涉及新型取代芳基衍生物，其制备方法以及用于抑制病毒复制和治疗病毒性疾病或障碍，如HIV和/或HCV感染的用途。
• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021011834A1

  公开（公告）日：2021-01-21

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。所披露的化合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。此外，本文还描述了与抗体构造物结合的化合物。
• Biphenyl derivatives
  申请人：——

  公开号：US20020040060A1

  公开（公告）日：2002-04-04

  The invention relates to compounds of the formula 1 wherein R is hydrogen, lower alkyl, lower alkoxy, halogen, amino, —N(R 6 ) 2 or trifluoromethyl; R 1 is hydrogen, lower alkoxy or halogen; R and R 1 may be together —CH═CH—CH═CH—; R 2 is halogen, lower alkyl or trifluoromethyl; R 3 is hydrogen or lower alkyl; R 4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl; R 5 is hydrogen, nitro, amino or —N(R 6 ) 2 ; R 6 is hydrogen or lower alkyl; X is —C(O)N(R 6 )—, —(CH 2 ) n O—, —(CH 2 )—,—N(R 6 )—, —N(R 6 )C(O)— or —N(R 6 )(CH 2 ) n —; and n is I or 2; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I may be used for the treatment of diseases related to the NK-l receptor.

  本发明涉及化合物公式1，其中R为氢、低级烷基、低级烷氧基、卤素、氨基、-N(R6)2或三氟甲基；R1为氢、低级烷氧基或卤素；R和R1可以结合成-CH═CH-CH═CH-；R2为卤素、低级烷基或三氟甲基；R3为氢或低级烷基；R4为氢或环状三级胺，可选择地被低级烷基取代；R5为氢、硝基、氨基或-N(R6)2；R6为氢或低级烷基；X为-C(O)N(R6)-、-(CH2)nO-、-( )-、-N(R6)-、-N(R6)C(O)-或-N(R6)( )n-；n为1或2；以及其药学上可接受的酸加盐。公式I的化合物可用于治疗与NK-l受体相关的疾病。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。